OBJECTIVES: Host gene expression signatures discriminate bacterial and viral infection but have not been translated to a clinical test platform. This study enrolled an independent cohort of patients to describe and validate a first-in-class host response bacterial/viral test. DESIGN: Subjects were recruited from 2006 to 2016. Enrollment blood samples were collected in an RNA preservative and banked for later testing. The reference standard was an expert panel clinical adjudication, which was blinded to gene expression and procalcitonin results. SETTING: Four U.S. emergency departments. PATIENTS: Six-hundred twenty-three subjects with acute respiratory illness or suspected sepsis. INTERVENTIONS: Forty-five-transcript signature measured on the BioFire FilmArray System (BioFire Diagnostics, Salt Lake City, UT) in ~45 minutes. MEASUREMENTS AND MAIN RESULTS: Host response bacterial/viral test performance characteristics were evaluated in 623 participants (mean age 46 yr; 45% male) with bacterial infection, viral infection, coinfection, or noninfectious illness. Performance of the host response bacterial/viral test was compared with procalcitonin. The test provided independent probabilities of bacterial and viral infection in ~45 minutes. In the 213-subject training cohort, the host response bacterial/viral test had an area under the curve for bacterial infection of 0.90 (95% CI, 0.84-0.94) and 0.92 (95% CI, 0.87-0.95) for viral infection. Independent validation in 209 subjects revealed similar performance with an area under the curve of 0.85 (95% CI, 0.78-0.90) for bacterial infection and 0.91 (95% CI, 0.85-0.94) for viral infection. The test had 80.1% (95% CI, 73.7-85.4%) average weighted accuracy for bacterial infection and 86.8% (95% CI, 81.8-90.8%) for viral infection in this validation cohort. This was significantly better than 68.7% (95% CI, 62.4-75.4%) observed for procalcitonin (p < 0.001). An additional cohort of 201 subjects with indeterminate phenotypes (coinfection or microbiology-negative infections) revealed similar performance. CONCLUSIONS: The host response bacterial/viral measured using the BioFire System rapidly and accurately discriminated bacterial and viral infection better than procalcitonin, which can help support more appropriate antibiotic use.
OBJECTIVES: Host gene expression signatures discriminate bacterial and viral infection but have not been translated to a clinical test platform. This study enrolled an independent cohort of patients to describe and validate a first-in-class host response bacterial/viral test. DESIGN: Subjects were recruited from 2006 to 2016. Enrollment blood samples were collected in an RNA preservative and banked for later testing. The reference standard was an expert panel clinical adjudication, which was blinded to gene expression and procalcitonin results. SETTING: Four U.S. emergency departments. PATIENTS: Six-hundred twenty-three subjects with acute respiratory illness or suspected sepsis. INTERVENTIONS: Forty-five-transcript signature measured on the BioFire FilmArray System (BioFire Diagnostics, Salt Lake City, UT) in ~45 minutes. MEASUREMENTS AND MAIN RESULTS: Host response bacterial/viral test performance characteristics were evaluated in 623 participants (mean age 46 yr; 45% male) with bacterial infection, viral infection, coinfection, or noninfectious illness. Performance of the host response bacterial/viral test was compared with procalcitonin. The test provided independent probabilities of bacterial and viral infection in ~45 minutes. In the 213-subject training cohort, the host response bacterial/viral test had an area under the curve for bacterial infection of 0.90 (95% CI, 0.84-0.94) and 0.92 (95% CI, 0.87-0.95) for viral infection. Independent validation in 209 subjects revealed similar performance with an area under the curve of 0.85 (95% CI, 0.78-0.90) for bacterial infection and 0.91 (95% CI, 0.85-0.94) for viral infection. The test had 80.1% (95% CI, 73.7-85.4%) average weighted accuracy for bacterial infection and 86.8% (95% CI, 81.8-90.8%) for viral infection in this validation cohort. This was significantly better than 68.7% (95% CI, 62.4-75.4%) observed for procalcitonin (p < 0.001). An additional cohort of 201 subjects with indeterminate phenotypes (coinfection or microbiology-negative infections) revealed similar performance. CONCLUSIONS: The host response bacterial/viral measured using the BioFire System rapidly and accurately discriminated bacterial and viral infection better than procalcitonin, which can help support more appropriate antibiotic use.
Authors: Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli Journal: N Engl J Med Date: 2015-07-14 Impact factor: 91.245
Authors: Seth W Glickman; Charles B Cairns; Ronny M Otero; Christopher W Woods; Ephraim L Tsalik; Raymond J Langley; Jennifer C van Velkinburgh; Lawrence P Park; Lawrence T Glickman; Vance G Fowler; Stephen F Kingsmore; Emanuel P Rivers Journal: Acad Emerg Med Date: 2010-04 Impact factor: 3.451
Authors: Prashant Mahajan; Nathan Kuppermann; Asuncion Mejias; Nicolas Suarez; Damien Chaussabel; T Charles Casper; Bennett Smith; Elizabeth R Alpern; Jennifer Anders; Shireen M Atabaki; Jonathan E Bennett; Stephen Blumberg; Bema Bonsu; Dominic Borgialli; Anne Brayer; Lorin Browne; Daniel M Cohen; Ellen F Crain; Andrea T Cruz; Peter S Dayan; Rajender Gattu; Richard Greenberg; John D Hoyle; David M Jaffe; Deborah A Levine; Kathleen Lillis; James G Linakis; Jared Muenzer; Lise E Nigrovic; Elizabeth C Powell; Alexander J Rogers; Genie Roosevelt; Richard M Ruddy; Mary Saunders; Michael G Tunik; Leah Tzimenatos; Melissa Vitale; J Michael Dean; Octavio Ramilo Journal: JAMA Date: 2016 Aug 23-30 Impact factor: 56.272
Authors: Rachael E Mahle; Sunil Suchindran; Ricardo Henao; Julie M Steinbrink; Thomas W Burke; Micah T McClain; Geoffrey S Ginsburg; Christopher W Woods; Ephraim L Tsalik Journal: Clin Infect Dis Date: 2021-08-16 Impact factor: 9.079
Authors: Rebecca G Wallihan; Nicolás M Suárez; Daniel M Cohen; Mario Marcon; Melissa Moore-Clingenpeel; Asuncion Mejias; Octavio Ramilo Journal: Front Cell Infect Microbiol Date: 2018-10-30 Impact factor: 5.293
Authors: Grace C Lee; Kelly R Reveles; Russell T Attridge; Kenneth A Lawson; Ishak A Mansi; James S Lewis; Christopher R Frei Journal: BMC Med Date: 2014-06-11 Impact factor: 8.775
Authors: Ian S Jaffe; Anja K Jaehne; Eugenia Quackenbush; Emily R Ko; Emanuel P Rivers; Micah T McClain; Geoffrey S Ginsburg; Christopher W Woods; Ephraim L Tsalik Journal: Open Forum Infect Dis Date: 2021-11-10 Impact factor: 3.835
Authors: Scott C Brakenridge; Uan-I Chen; Tyler Loftus; Ricardo Ungaro; Marvin Dirain; Austin Kerr; Luer Zhong; Rhonda Bacher; Petr Starostik; Gabriella Ghita; Uros Midic; Dijoia Darden; Brittany Fenner; James Wacker; Philip A Efron; Oliver Liesenfeld; Timothy E Sweeney; Lyle L Moldawer Journal: JAMA Netw Open Date: 2022-07-01
Authors: Zachary E Holcomb; Julie M Steinbrink; Aimee K Zaas; Marisol Betancourt; Jennifer L Tenor; Dena L Toffaletti; J Andrew Alspaugh; John R Perfect; Micah T McClain Journal: J Fungi (Basel) Date: 2022-04-22
Authors: Ephraim L Tsalik; Cassandra Fiorino; Ammara Aqeel; Yiling Liu; Ricardo Henao; Emily R Ko; Thomas W Burke; Megan E Reller; Champica K Bodinayake; Ajith Nagahawatte; Wasantha K Arachchi; Vasantha Devasiri; Ruvini Kurukulasooriya; Micah T McClain; Christopher W Woods; Geoffrey S Ginsburg; L Gayani Tillekeratne; Klaus Schughart Journal: Front Immunol Date: 2021-10-27 Impact factor: 8.786
Authors: Melissa Ross; Ricardo Henao; Thomas W Burke; Emily R Ko; Micah T McClain; Geoffrey S Ginsburg; Christopher W Woods; Ephraim L Tsalik Journal: PLoS One Date: 2021-12-14 Impact factor: 3.752
Authors: Nicholas Bodkin; Melissa Ross; Micah T McClain; Emily R Ko; Christopher W Woods; Geoffrey S Ginsburg; Ricardo Henao; Ephraim L Tsalik Journal: Genome Med Date: 2022-02-21 Impact factor: 11.117
Authors: Emily R Ko; Ricardo Henao; Katherine Frankey; Elizabeth A Petzold; Pamela D Isner; Anja K Jaehne; Nakia Allen; Jayna Gardner-Gray; Gina Hurst; Jacqueline Pflaum-Carlson; Namita Jayaprakash; Emanuel P Rivers; Henry Wang; Irma Ugalde; Siraj Amanullah; Laura Mercurio; Thomas H Chun; Larissa May; Robert W Hickey; Jacob E Lazarus; Shauna H Gunaratne; Daniel J Pallin; Guruprasad Jambaulikar; David S Huckins; Krow Ampofo; Ravi Jhaveri; Yunyun Jiang; Lauren Komarow; Scott R Evans; Geoffrey S Ginsburg; L Gayani Tillekeratne; Micah T McClain; Thomas W Burke; Christopher W Woods; Ephraim L Tsalik Journal: JAMA Netw Open Date: 2022-04-01
Authors: Nam K Tran; Samer Albahra; Larissa May; Sarah Waldman; Scott Crabtree; Scott Bainbridge; Hooman Rashidi Journal: Clin Chem Date: 2021-12-30 Impact factor: 12.167